Elizabeth Goodrich

MilliporeSigma
Technical Director
Elizabeth Goodrich is a biotechnology engineer with over 30 years of experience in protein purification development and scale-up as well as system design and process automation. She began her career at Genentech in the Late-Stage Recovery Process Development organization. During her tenure at MilliporeSigma, she has held a variety of technical positions on both the commercial and R&D sides of the organization. Beth is currently a Technical R&D Director in the Single-use and Integrated Systems team within Process Solutions Division and is focused on bringing novel and sustainable solutions to the industry to enable intensified and continuous biomanufacturing. She holds a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology.

Related Articles

Figure 1: Batch manufacturing process vs. a low pH iVI process.
Technical
Continuous Process: Implementing Low pH Viral Inactivation in a Continuous Process

Viral inactivation (VI) is a critical step in ensuring the safety of monoclonal antibody (mAb), Fc fusion, and recombinant protein therapeutics and it is typically an important component of an overall virus control strategy for downstream biotherapeutic production processes. Considerations for successful implementation of an inline VI process are discussed in this article.